IAM1363 is a selective and brain-penetrant small molecule inhibitor of HER2 signaling for solid tumors. Iambic has dosed its first patient in a Phase I/Ib trial (NCT06253871) designed to evaluate the tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of IAM1363, both as monotherapy and in combination with trastuzumab in patients with advanced HER2 cancers. Trastuzumab is a HER2/neu receptor antagonist marketed as Herceptin^® by Roche and its Genentech subsidiary.